[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-385683-105":59,"doc-detail-385683-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","circulating-tumor-dna-in-head-and-neck-squamous-cell-carcinoma-review","Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma - Review","","Head and neck squamous cell carcinoma (HNSCC) requires biomarkers that enable early detection, prediction of relapse, and assessment of treatment resistance. This review explains how liquid biopsies detect tumor-related cell-free DNA (cfDNA) shed into plasma to non-invasively monitor disease over time. It outlines the biological basis in HNSCC genetics and tumor heterogeneity, and highlights clinical relevance for minimal residual disease and genomic profiling. The review also addresses technical challenges that limit routine clinical implementation and widespread use.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumor-dna-in-head-and-neck-squamous-cell-carcinoma-review/385683/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-in-head-and-neck-squamous-cell-carcinoma-review/385683.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is circulating tumor DNA used for in HNSCC?","Question",{"text":113,"@type":114},"Circulating tumor DNA is used via liquid biopsy to analyze cfDNA in plasma for detection of minimal residual cancer, genomic tumor profiling, and monitoring over time.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why might liquid biopsy be useful for head and neck squamous cell carcinoma?",{"text":118,"@type":114},"It may help because HNSCC shows genetic tumor heterogeneity and conventional imaging has sensitivity limitations, making non-invasive molecular monitoring valuable.",{"name":120,"@type":111,"acceptedAnswer":121},"What limits the widespread clinical use of liquid biopsy in HNSCC?",{"text":122,"@type":114},"Technical challenges need to be overcome before liquid biopsy can be routinely implemented in clinical management.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},385683,1790332537,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","cancers   \nReview  \nCirculating Tumor DNA in Head and Neck Squamous Cell Carcinoma  \nAnna Brandt 1, Benjamin Thiele 2, Christoph Schultheiß 3, Eveline Daetwyler 4 and Mascha Binder 3,4, *  \nCitation: Brandt, A.; Thiele, B.; Schultheiß, C.; Daetwyler, E.; Binder, M. Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. Cancers 2023, 15, 2051 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers15072051  \nAcademic Editors: Sophie Martin, Alain C. Jung and Mickaël Burgy  \nReceived: 1 March 2023  \nRevised: 21 March 2023  \nAccepted: 28 March 2023  \nPublished: 30 March 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Internal Medicine 5, Hematology and Oncology, University Hospital of Erlangen,  \n91054 Erlangen, Germany  \n2 Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany  \n3 Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120 Halle (Saale), Germany  \n4 Division of Medical Oncology, University Hospital Basel, 4031 Basel, Switzerland  \n* Correspondence: mascha.binder@unibas.ch; Tel.: +41-612-655-074; Fax: +41-612-655-316  \nSimple Summary: Head and Neck Squamous Cell Carcinomas (HNSCCs) are cancers that originate from cells of the head and neck region, including the mouth, nose, and throat. The diversity of these cell types is also mirrored by the high number of different mutations that promote cancer development and progression. For the clinical management of this disease, it is important to identify biomarkers that allow early detection or predict relapse and resistance to therapy. A non-invasive way to monitor these markers over time are so called liquid biopsies, which mostly refers to the detection and analysis of tumor cells or cell-free DNA (cfDNA) in the blood of patients. This review summarizes our current understanding of HNSCC genetics and discusses how the detection of genetic variation in the cfDNA of HNSCC patients can be used to monitor disease and guide therapy.  \nAbstract: Tumors shed cell-free DNA (cfDNA) into the plasma.“Liquid biopsies” are a diagnostic test to analyze cfDNA in order to detect minimal residual cancer, profile the genomic tumor landscape, and monitor cancers non-invasively over time. This technique may be useful in patients with head and neck squamous cell carcinoma (HNSCC) due to genetic tumor heterogeneity and limitations in imaging sensitivity. However, there are technical challenges that need to be overcome for the widespread use of liquid biopsy in the clinical management of these patients. In this review, we discuss our current understanding of HNSCC genetics and the role of cfDNA genomic analyses as an emerging precision diagnostic tool.  \nKeywords: head and neck squamous cell carcinoma (HNSCC); cell-free DNA (cfDNA); liquid biopsy; monitoring; resistance; prognostication  \n1. Introduction  \nHead and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the epithelial cells that line regions of the head and neck, including the mouth, nose, and throat (Figure 1) [1–4] . HNSCC is the seventh most common cancer worldwide, accounting for 3% of all new cancers and for 1.5% of all cancer deaths according to global cancer statistics (GLOBOCAN) [5] . Risk factors for HNSCC include tobacco and alcohol use, viral infections (human papillomavirus [HPV], Epstein-Barr virus [EBV]), poor oral hygiene, exposure to certain chemicals as well as some genetic syndromes, such as Fanconi anemia [1–4,6] . The majority of patients are diagnosed with loc","cbCaij0rMkMAaJru","https://ap.wps.com/l/cbCaij0rMkMAaJru","pdf",1581653,"English","# Introduction\n## Liquid biopsies and liquid-biomarker rationale\n# Abstract\n## Liquid biopsy goals and clinical utility\n## Technical challenges\n# Keywords","[{\"question\":\"What is circulating tumor DNA used for in HNSCC?\",\"answer\":\"Circulating tumor DNA is used via liquid biopsy to analyze cfDNA in plasma for detection of minimal residual cancer, genomic tumor profiling, and monitoring over time.\"},{\"question\":\"Why might liquid biopsy be useful for head and neck squamous cell carcinoma?\",\"answer\":\"It may help because HNSCC shows genetic tumor heterogeneity and conventional imaging has sensitivity limitations, making non-invasive molecular monitoring valuable.\"},{\"question\":\"What limits the widespread clinical use of liquid biopsy in HNSCC?\",\"answer\":\"Technical challenges need to be overcome before liquid biopsy can be routinely implemented in clinical management.\"}]","Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma - Review | PDF",1790270564,48]